http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2637631-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_905e7c75b958e4fb9bc771bd7a5b809b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate | 2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b495951e46d1e3ee323bbc9fd90f38c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70a399556c23e789aade862c0134d714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7005c9523fff9de4aca6287beed4f862 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb16c861473daa86f0392e71d61b1caa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_447cf0f0f49a16eee468f8ce980c5837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaacbd423ff5a161d226372ee63a3e4d |
| publicationDate | 2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2637631-C2 |
| titleOfInvention | Method for immune therapy of chronic viral hepatitis c |
| abstract | FIELD: medicine. n SUBSTANCE: patient receives autologous dendritic cells that are generated from peripheral blood cells using differentiation inducers loaded with antigens encoding viral proteins and induced to further maturation. Interleukin-2 is prescribed as adjuvant. As a antigen, a combination of fragments of recombinant viral Core (1-120 aq) and NS3 (1192-1457 aq) proteins is used, DC maturation is induced with azoximer bromide, dendritic cells are administered as 2 courses of subcutaneous vaccination, combining DC administration with subcutaneous intermittent injections of recombinant interleukin-2 as an adjuvant non-specific therapy for patients with chronic viral hepatitis C. Granulocyte-macrophage colony-stimulating factor and interferon-alpha are used as dendritic cells differentiation inducers. n EFFECT: method enables an increase of clinical effectiveness. n 2 cl, 2 tbl, 3 ex |
| priorityDate | 2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 499.